Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The company is ending…
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere…
Moderna’s efforts to advance its cancer pipeline “make sense” against the backdrop of a more skeptical U.S. government attitude toward infectious disease vaccines, the company’s oncology chief told Fierce. The…